, Volume 65, Issue 17, pp 2463–2479

Issues for Clinical Drug Development in Neurodegenerative Diseases

Review Article


Neurodegenerative diseases pose specific challenges for drug development. These diseases typically have a slow and variable clinical course, an insidious onset, and symptom expression is only observed when a significant proportion of neurons are already lost. It is important to identify vulnerability factors and other determinants of clinical course in order to be able in the future to select patient populations for clinical trials with a predictable prognosis. The neurodegenerative process itself is not amenable to direct observation and, thus, cannot be monitored in clinical trials. For this reason, surrogate biomarkers are required for use as outcome parameters. In this respect, magnetic resonance imaging has proved valuable for assessing disease activity and progression in multiple sclerosis. Rating scales are of use as outcome measures but, as these generally measure symptom severity, they are most appropriate for use in assessing symptomatic treatments. Survival has been used with success as an outcome measure in trials in amyotrophic lateral sclerosis, where disease progression is rapid. The optimal outcome measure, the sample size required and the treatment duration need to be chosen in relation to the phase of the disease. Potential new treatments can be chosen based upon new knowledge of the genetics and physiopathology of neurodegenerative diseases and, in some cases, screened in transgenic mouse models, although it should be recognised that the validity of these models in terms of treatment response has yet to be established empirically.


  1. 1.
    Hauw JJ, Dubois B, Verny M, et al. La maladie d’Alzheimer. Paris: Editions John Libbey Eurotext — collection pathologie science formation, 1997Google Scholar
  2. 2.
    Sobue G, Sahabashi KM, Takahashi A, et al. Degenerating compartment and functioning compartment of motor neurons in ALS: possible process of motor neuron loss. Neurology 1983; 33: 654–7PubMedCrossRefGoogle Scholar
  3. 3.
    Hedreen JC, Peyser CE, Folstein SE, et al. Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease. Neurosci Lett 1991; 133: 257–61PubMedCrossRefGoogle Scholar
  4. 4.
    Cifelli A, Arridge M, Jezzard P, et al. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002; 52: 650–3PubMedCrossRefGoogle Scholar
  5. 5.
    Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1991; 54: 388–96PubMedCrossRefGoogle Scholar
  6. 6.
    Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging: measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290–7Google Scholar
  7. 7.
    Dib M. Amyotrophic lateral sclerosis: progress and prospects for treatment. Drugs 2003; 63(3): 289–310PubMedCrossRefGoogle Scholar
  8. 8.
    Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology 2000; 54: 452–8Google Scholar
  9. 9.
    Bensimon G, Lacomblez L, Delumeau JC, et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249: 609–15PubMedCrossRefGoogle Scholar
  10. 10.
    Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–91PubMedCrossRefGoogle Scholar
  11. 11.
    Validation of surrogate from endpoint multiple trials. National Institutes of Health, 1998 [online]. Available from URL: http://www4.od.nih.gov/biomarkers [Accessed 2005 Sep 26]
  12. 12.
    Desnuelle C, Dib M, Garrel C, et al. A double-blind, placebocontrolled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis: ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 9–18PubMedCrossRefGoogle Scholar
  13. 13.
    Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 1995; 38: 643–8PubMedCrossRefGoogle Scholar
  14. 14.
    Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937–45PubMedCrossRefGoogle Scholar
  15. 15.
    Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloidl-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094–103PubMedCrossRefGoogle Scholar
  16. 16.
    Hampel H, Mitchell A, Blennow K, et al. Core biological marker candidates of Alzheimer’s disease: perspectives for diagnosis, prediction of outcome and reflection of biological activity. J Neural Transm 2004; 111: 247–72PubMedCrossRefGoogle Scholar
  17. 17.
    Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A betal-40, and A betal-42 (43) in Alzheimer’s disease: a study in Japan. Ann Neurol 1998; 44: 17–26PubMedCrossRefGoogle Scholar
  18. 18.
    Tapiola T, Pirttila T, Mikkonen M, et al. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer’s disease. Neurosci Lett 2000; 280: 119–22PubMedCrossRefGoogle Scholar
  19. 19.
    Sjogren M, Gustafsson K, Syversen S, et al. Treatment with simvastatin in patients with Alzheimer’s disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003; 16: 25–30PubMedCrossRefGoogle Scholar
  20. 20.
    Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease. Ann Neurol 1995; 38: 649–52PubMedCrossRefGoogle Scholar
  21. 21.
    Hock C, Golombowski S, Naser W, et al. Increased levels of Tau protein in cerebrospinal fluid of patients with Alzheimer’s disease: correlation with degree of cognitive impairment. Ann Neurol 1995; 37: 414–5PubMedCrossRefGoogle Scholar
  22. 22.
    Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology 1995; 45: 788–93PubMedCrossRefGoogle Scholar
  23. 23.
    Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study. J Neurol Neurosurg Psychiatry 1998; 64: 298–305PubMedCrossRefGoogle Scholar
  24. 24.
    Poser S, Zerr I, Schroeter A, et al. Clinical and differential diagnosis of Creutzfeldt-Jakob disease. Arch Virol Suppl 2000; 16: 153–9PubMedGoogle Scholar
  25. 25.
    Tschampa HJ, Neumann M, Zerr I, et al. Patients with Alzheimer’s disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001; 71: 33–9PubMedCrossRefGoogle Scholar
  26. 26.
    Huang N, Marie SK, Livramento JA, et al. 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology 2003 Aug 12; 61: 354–7PubMedCrossRefGoogle Scholar
  27. 27.
    Rothstein JD. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. Adv Neurol 1995; 68: 7–20PubMedGoogle Scholar
  28. 28.
    Ryberg H, Askmark H, Persson LI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand 2003; 108: 1–8PubMedCrossRefGoogle Scholar
  29. 29.
    Sormani MP, Bruzzi P, Comi G, et al. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 2002; 58: 417–21PubMedCrossRefGoogle Scholar
  30. 30.
    McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–7PubMedCrossRefGoogle Scholar
  31. 31.
    Wang D, Chalk JB, Rose SE, et al. MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer’s disease and normal aging. Magn Reson Imaging 2002; 20: 41–8Google Scholar
  32. 32.
    Jack Jr CR, Shiung MM, Gunter JL, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004; 62: 591–600PubMedCrossRefGoogle Scholar
  33. 33.
    Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer’s disease. Am J Psychiatry 2003; 160: 2003–11PubMedCrossRefGoogle Scholar
  34. 34.
    Brooks DJ. PET and SPECT studies in Parkinson’s disease. Baillieres Clin Neurol 1997; 6: 69–87PubMedGoogle Scholar
  35. 35.
    Piccini P. Neurodegenerative movement disorders: the contribution of functional imaging. Curr Opin Neurol 2004; 17: 459–66PubMedCrossRefGoogle Scholar
  36. 36.
    Stoof JC, Winogrodzka A, van Muiswinkel FL, et al. Leads for the development of neuroprotective treatment in Parkinson’s disease and brain imaging methods for estimating treatment efficacy. Eur J Pharmacol 1999; 375: 75–86PubMedCrossRefGoogle Scholar
  37. 37.
    Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653–61CrossRefGoogle Scholar
  38. 38.
    Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93–101PubMedCrossRefGoogle Scholar
  39. 39.
    Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004; 351: 2498–508PubMedCrossRefGoogle Scholar
  40. 40.
    LeWitt PA. Clinical trials of neuroprotection for Parkinson’s disease. Neurology 2004; 63 Suppl. 2: S23–31PubMedCrossRefGoogle Scholar
  41. 41.
    Cesaro P. Neuron transplantation and Parkinson disease. Rev Neurol 2002; 158 Spec. No. 1: S142–3PubMedGoogle Scholar
  42. 42.
    Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson’s disease. Florham Park (NJ): Macmillan Health Care Information, 1987: 153–63Google Scholar
  43. 43.
    Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 1996; 11: 136–42CrossRefGoogle Scholar
  44. 44.
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64PubMedGoogle Scholar
  45. 45.
    Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195–203PubMedCrossRefGoogle Scholar
  46. 46.
    Huntington Study Group. Dosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled study. Neurology 2003; 61: 1551–6CrossRefGoogle Scholar
  47. 47.
    Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 2003; 38: 547–54PubMedCrossRefGoogle Scholar
  48. 48.
    Kurtzke JF. Disability rating scales in multiple sclerosis. Ann N Y Acad Sci 1984; 436: 347–60PubMedCrossRefGoogle Scholar
  49. 49.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG) [published erratum appears in Ann Neurol 1996; 40: 480]. Ann Neurol 1996; 39: 285–94PubMedCrossRefGoogle Scholar
  50. 50.
    PRISMS (Prevention of Relapses and disability by Interferon-β 1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised, double-blind, placebo-controlled study of interferon-β 1 a in relapsing-remitting multiple sclerosis: clinical results. Lancet 1998; 352: 1498–504CrossRefGoogle Scholar
  51. 51.
    Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon beta-la in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry 1999; 67: 451–6PubMedCrossRefGoogle Scholar
  52. 52.
    Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001; 57: 1969–75PubMedCrossRefGoogle Scholar
  53. 53.
    Martinelli-Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003; 9: 349–55PubMedCrossRefGoogle Scholar
  54. 54.
    Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003; 9: 585–91PubMedCrossRefGoogle Scholar
  55. 55.
    Ford C, Johnson K, Brooks B, et al. Sustained efficacy and tolerability of glatiramer acetate in relapsing-remitting multiple sclerosis patients for over ten years [abstract]. Mult Scler 2003;9 Suppl. 1: S120Google Scholar
  56. 56.
    Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis: Northeast ALS Consortium. Neurology 2003; 61: 456–64PubMedCrossRefGoogle Scholar
  57. 57.
    Traynor BJ, Zhang H, Shefner JM, et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004; 63: 1933–5PubMedCrossRefGoogle Scholar
  58. 58.
    The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993; 328: 176–83CrossRefGoogle Scholar
  59. 59.
    Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease: Parkinson’s Disease Research Group of the United Kingdom. BMJ 1995; 311: 1602–7PubMedCrossRefGoogle Scholar
  60. 60.
    Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson’s Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson’s disease: further results of randomised trial and confidential inquiry. BMJ 1998; 316: 1191–6PubMedCrossRefGoogle Scholar
  61. 61.
    Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995; 38: 771–7PubMedCrossRefGoogle Scholar
  62. 62.
    Fillit HM. The pharmacoeconomics of Alzheimer’s disease. Am J Manag Care 2000; 6 (22 Suppl.): S1139–44PubMedGoogle Scholar
  63. 63.
    Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105–15PubMedCrossRefGoogle Scholar
  64. 64.
    Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebocontrolled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481–8PubMedCrossRefGoogle Scholar
  65. 65.
    Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia: Clinical Progression of Dementia Study Group. N Engl J Med 2001; 344: 1111–6PubMedCrossRefGoogle Scholar
  66. 66.
    Diesfeldt HFA, van Houte LR, Moerkens RM. Duration of survival in senile dementia. Acta Psychiatr Scand 1986; 73: 366–71PubMedCrossRefGoogle Scholar
  67. 67.
    Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347(9013): 1425–31PubMedGoogle Scholar
  68. 68.
    Forbes RB, Colville S, Cran GW, et al. Scottish Motor Neurone Disease Register. Unexpected decline in survival from amyotrophic lateral sclerosis/motor neurone disease. J Neurol Neurosurg Psychiatry 2004; 75: 1753–5Google Scholar
  69. 69.
    Couratier P, Druet-Cabanac M, Truong CT, et al. Interest of a computerized ALS database in the diagnosis and follow-up of patients with ALS. Rev Neurol 2000; 156: 357–63PubMedGoogle Scholar
  70. 70.
    Turner MR, Bakker M, Sham P, et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 15–21PubMedCrossRefGoogle Scholar
  71. 71.
    Traynor BJ, Alexander M, Corr B, et al. An outcome study of riluzole in amyotrophic lateral sclerosis-a population-based study in Ireland, 1996–2000. J Neurol 2003; 250: 473–9PubMedCrossRefGoogle Scholar
  72. 72.
    Marras C, McDermott MP, Rochon PA, et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 2005; 64: 87–93PubMedCrossRefGoogle Scholar
  73. 73.
    Rosen DR, Sapp P, O’Regan J, et al. Genetic linkage analysis of familial amyotrophic lateral sclerosis using human chromosome 21 microsatellite DNA markers. Am J Med Genet 1994; 51: 61–9PubMedCrossRefGoogle Scholar
  74. 74.
    Dal Canto MC, Gurney ME. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995; 676: 25–40CrossRefGoogle Scholar
  75. 75.
    Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147–57PubMedCrossRefGoogle Scholar
  76. 76.
    Maragakis NJ, Jackson M, Ganel R, et al. Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett 2003; 338: 107–10PubMedCrossRefGoogle Scholar
  77. 77.
    Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347–50PubMedCrossRefGoogle Scholar
  78. 78.
    Groeneveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–45PubMedCrossRefGoogle Scholar
  79. 79.
    Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656–61PubMedCrossRefGoogle Scholar
  80. 80.
    Bates GP, Mangiarini L, Mahal A, et al. Transgenic models of Huntington’s disease. Hum Mol Genet 1997; 6: 1633–7PubMedCrossRefGoogle Scholar
  81. 81.
    Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995; 373: 523–7PubMedCrossRefGoogle Scholar
  82. 82.
    Dupuis L, Gonzalez de Aguilar JL, di Scala F, et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 358–65PubMedCrossRefGoogle Scholar
  83. 83.
    Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993 Aug 13; 261(5123): 921–3PubMedCrossRefGoogle Scholar
  84. 84.
    Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753–7PubMedCrossRefGoogle Scholar
  85. 85.
    Muir KW, Lees KR. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev 2003; (3): CD001244Google Scholar
  86. 86.
    Lutsep HL, Clark WM. Current status of neuroprotective agents in the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep 2001; 1: 13–8PubMedCrossRefGoogle Scholar
  87. 87.
    Evans JG, Wilcock G, Birks J. Evidence-based pharmacotherapy of Alzheimer’s disease. Int J Neuropsychopharmacol 2004; 7: 351–69PubMedCrossRefGoogle Scholar
  88. 88.
    Louvel E, Hugon J, Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol Sci 1997; 18: 196–203PubMedGoogle Scholar
  89. 89.
    Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis: rhCNTF ALS Study Group. Ann Neurol 1996; 39: 256–60PubMedCrossRefGoogle Scholar
  90. 90.
    Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Expert Opin Drug Saf 2004; 3: 525–34PubMedCrossRefGoogle Scholar
  91. 91.
    Ince PG, Shaw PJ, Slade JY, et al. Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn Superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol 1996; 92: 395–403PubMedCrossRefGoogle Scholar
  92. 92.
    Waubant E, Vukusic S, Gignoux L, et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184–9PubMedCrossRefGoogle Scholar
  93. 93.
    Tanaka Y, Hanyu H, Sakurai H, et al. Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer’s disease patients. Dement Geriatr Cogn Disord 2003; 16: 119–25PubMedCrossRefGoogle Scholar
  94. 94.
    Kipnis J, Schwartz M. Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders. Trends Mol Med 2002; 8: 319–23PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Service de NeurologieHôpital de la SalpêtrièreParisFrance

Personalised recommendations